











SEMPERIT GROUP FY 2023 INVESTOR PRESENTATION

Karl Haider, CEO Helmut Sorger, CFO

19 March 2024

Key Highlights & Strategy (p.2)

Operational Performance (p.11)

Financial Performance (p.16)

Outlook (p.27)

Appendix (p.33)





Leading industrial elastomer specialist with diversified product portfolio

Semperit is a global pioneer in the production of high-quality elastomer applications for industrial clients with a 200 years' history.

We are constantly expanding our global footprint — with technologically sophisticated innovations that keep the world of our customers running.

OUR VISION:

Addressing global challenges through sophisticated elastomer applications

IMPORTANT MEGATRENDS

Climate change | Demographics | Urbanisation | Mobility | Electrification

Leading market position

Among the world's leading industrial players with our elastomer products

Market leading brands, customer-focused approach and a globally diversified sales network

Technological edge

Strong track record in synthetic and natural rubber applications complemented by new expansion into liquid silicon rubber

Technological lead based on continuous innovation and customer centricity

Resilient business model

Diversified portfolio serving a broad customer base in numerous industries

Streamlined organisation with two separate divisions applying cost leadership with a particular focus on customised technical solutions

Strong industrial platform

Powerful set-up based on local knowledge and global powerhouse

Industrial customer solutions and drive for operational excellence at all levels to remain competitive

Lean management

OUR MISSION:

A global leader with advanced and sustainable elastomer materials and solutions





Strategic focus: profitable growth, customer intimacy and technology leadership

New divisional structure evolves around Semperit's two main business models and serves as ideal platform for focused organic and inorganic growth – while reducing complexity and enabling to scale up business



Semperit Industrial Applications

Cost leadership to harvest volume business

- Cost leadership
- Process and product innovation
- Mostly standardised highperformance products
- Lower complexity in product portfolio
- Qualified sales team & high level of sales excellence
- High degree of unification of products, processes and equipment across our factories



Semperit Engineered Applications

Attractive niche specialisation

- Leveraging on know-how and engineered technology
- Focus on attractive niche markets
- Strong focus on customer
- High level of customisation
- Standardised innovation & R&D process, reliable & plannable time to market
- Qualified sales team & application engineering
- Project- & tender business





Strategic focus for Semperit Industrial Applications



HOSES – Cost leadership and enlargement of product range

DH5 investment: Capacity expansion in Odry/CZ will strengthen Semperit's position as one of the global market leaders for hydraulic hoses.

Cost leadership – set by DH5 as new efficiency benchmark and roll out to other plants

Strengthening and enlargement of highly competitive product range (e.g. new soft spiral hose range)

Organic growth strategy for industrial hoses focusing on product and market development for selected new applications (e.g. peristaltic pumps, concrete pumps, food etc.)

Geographic expansion in North America



PROFILES – Focus on Europe and US

Strengthening our position in the European construction and industrial markets

Geographic expansion in North America

Enlarging the customer base via sales excellence and customer intimacy

Focus on cost and complexity reduction

Recycling: Development of EPDM profiles with a portion of reclaimed materials





Strategic focus for Semperit Engineered Applications



BELTING – Levering on existing capacity



Coherent product strategy – heavy and medium strength steel belts and performance textile belts

- Excellent price / performance ratio
- Benchmark in technical support

Working on strategic partnerships with international mining groups and increasing the market share in mining applications (excl. lignite)

Concentration on efficiency and capacity utilisation

Geographic set-up

Defend and further expand current growth markets



FORM – Profitable niches and optimized margins

Strong focus on growth with new Product-Market-Combinations (PMC's) which are highly margin accretive

Portfolio streamlining to boost margins

Extension of end-to-end application know how to grow with customised product/market strategies

Playing the niche (market wise) supported by economy of scale (operations wise) using an increased level of automation and streamlined costs

Geographic focus on growth markets in Europe and expansion into Americas and APAC



RICO – Platform for organic and inorganic growth

Expansion in Thalheim (Austria)

recently completed (incl. 3 production facilities, high-bay warehouse, handling areas and additional office space on an area of more than 10,000 sqm)

Planning production expansion in **US** and **Switzerland**

Considering smaller add-on acquisitions to exploit market growth (market for silicone products in Western Europe and the USA to grow by around 7% p.a. until 2027) and leverage tooling expertise

Geographic expansion US and APAC





2023: Semperit delivered as promised Setting the stage for a new growth platform





Liquid Silicone Rubber (LSR) – strengthening of technological leadership and levering on substantial market growth

Capacity extension at Rico in Thalheim underpins our technological lead in injection molding tools and automation



- Acquisition of Rico allows complementary offering with high performance advanced materials focusing on liquid silicone rubber (LSR)
- Investment of around EUR 40m in plant and capacity expansion by 2028
- Smaller add-on acquisitions to exploit substantial market growth for silicone products in Western Europe and the USA (expected CAGR of ~7% p.a. until 2027) and leverage tooling expertise



Hoses – EUR 100m investment in Europe's largest hose production

Growth investment to strengthen our position and competitiveness as one of the top global players for hoses

- Capacity extension by 24 million meters p.a. plus 3.6 million meters (relocation) up to 135 million meters p.a. in Odry resp. up to 190 million meters overall hoses production
- Ramp up of new production facilities in stages beginning in 2025 – full capacity in 2030
- Total investment of around EUR 100m
- Benefits include higher efficiency in supply chains and deliveries, reduced emissions and lower transport costs
- Focus on a high degree of automation and sustainability







Operational Performance (p.11)

Financial Performance (p.16)

Outlook (p.27)

Appendix (p.33)





Divisional developments of revenues along two very different success factors

Divisional structure evolves around Semperit's two main business models


Semperit Industrial Applications Semperit Engineered Applications 36% 46% 48% 57% 2022 2023 6% **Surgical Operations**




Semperit Industrial Applications 2023

High cyclicality of commodity business









- Hoses: restrained customer behavior based on low market demand and weakness in short-cycle business
- Profiles: impact from weak construction industry with continuing low but stable level and low backlog
- Annual sales down by 27% and EBITDA by 47% as volumes were down
- End of destocking effects but headwinds of slower economic growth
- Focus on efficient and agile organization, customer intimacy and economies of scale – overhead cost measures effective




Semperit Engineered Applications 2023

Tailwinds from mining, lower raw materials prices and RICO contribution







- Belting: ongoing late-cycle demand in mining with supportive pricing and ongoing solid demand
- Form: sales and profits particularly encouraging in mountain applications, solid after-sales handrail business
- Rico: sales contribution of EUR 37.2m since August 2023 and EBITDA of EUR 7.6m based on strong demand in the areas of health systems, food products and mobility
- Annual sales up by 24% and EBITDA by 36% as prices remained high and portfolio optimization supported margins

¹ EBITDA and EBITDA margin Q3 2023 and Q4 2023 adjusted by EUR 4.1m and EUR 2.3m respectively, for one off effects related to the acquisition of the Rico Group



Key focus points in 2023


- Competitive ESG rating year:
 - EcoVadis Platinum




CDP Climate C, Forest C,
 Water D (first time disclosing, rating is private)

- Climate scenario analysis as an important building block of EU Taxonomy and ESRS
- Amended strategy with additional focus on D&I

Performance 2023







-1%

2022

-8%

2022

15%

10%

5%

0%

15%

10%

5%

0%

0%

2023

-4%

2023



Key Highlights & Strategy (p.2)

Operational Performance (p.11)

Financial Performance (p.16)

Outlook (p.27)

Appendix (p.33)



Financial highlights 2023

New financial arrangements since Q1'2023 based on strategic priorities of industrial transformation Lean management and structural cost savings to support operating leverage -Original annual runrate target of 10m exceeded

Main focus on free cashflow for growth investments,

dividends

Strong balance sheet structure

Base dividend at EUR 1.50 per share and additional dividend of EUR 3.00 after sale of Sempermed

Financing line extended to EUR 360m

EUR 5.8m of overhead reduction already achieved

EUR 111.5m after sale of examination gloves business



Financial net debt at EUR 115.2m and net debt/ EBITDA at 1.6x



EUR 92.6m dividends in total paid












Overview of financial KPIs 2021-2023

	2021	2022	2023	Δ 2022/2023
Revenues, in EUR m	1,182.2	779.8	721.1	-7.5%
EBITDA , in EUR m	361.8	100.5	71.8	-28.5%
EBITDA margin, in %	30.6	12.9	10.0	-2.9PP
EBIT, in EUR m	315.0	62.1	34.6	-44.3%
EBIT margin, in %	26.6	8.0	4.8	-3.2PP
Earnings after tax from continued op. in EUR m	3.6	38.4	24.9	-35.2%
Free Cashflow ¹ , in EUR m	238.4	-2.8	26.3	n/a
CAPEX ² , in EUR m	47.9	54.5	55.6	2.0%

¹ Free Cashflow before proceeds from sale of the medical business and strategic growth projects ² 2023 CAPEX at EUR 55.6m before M&A: includes EUR 36.2m for maintenance and small projects and EUR 19.4m for strategic Growth projects – Rico acquisition at EUR 164.8m not included



Detail on Last Twelve Month (LTM) view



- Cyclical downturn since Q1'2023 combined with inventory digestion destocking effect most notable in 2022-23
- Volumes in decline while prices are stable, margins supported by lower raw materials and energy prices
- Q4'2023 partly impacted by seasonality, planned downtime during the winter period and cost savings
- Further focus on agile and slim organization, cash generation and strong balance sheet


LTM Revenue in EUR m — LTM EBITDA margin in %





Major drivers of operating performance – main building blocks of EBITDA-bridge

in EUR m




Rico effects shown separately, thus price and volume effects of sales, change in inventories, cost of materials, logistics, personnel expenditures, misc. and cost savings do not include Rico-figures





Components of Working Capital¹

in EUR m





Trade Working Capital in % of LTM revenues;

¹ Since 31 December 2022 without Sempermed (examination operations); as of 30 September 2023 including Rico for five months



CAPEX development 2021-2023




¹ 2021 and 2022 included each EUR 17mn CAPEX of the discontinued operations for the production line P7+ in Kamunting, Malaysia






Free cash flow before strategic growth investment



Financial Net Debt Development 2023

- Improved operating cash flow generation on the back of proactive working capital management
- Proceeds from company disposals are major driving force of higher FCF in 2023
- Higher FCF were used for acquisition of Rico Group, strategic growth investments (DH5, Rico) and dividends






Robust balance sheet structure and financial profile

Balance sheet structure

Balance sheet 31/12/2023: EUR 938m Balance sheet 31/12/2022: EUR 843m




Financial profile as of 31 December 2023

- Cash and cash equivalents at EUR 113m
- New financing of EUR 360m arranged EUR 33m already used for Odry DH5 extension and EUR 110m line used for Rico acquisition by end of December
- Financial liabilities at EUR 228m, have now increased due to new financing arrangements and RICO integration
- Net financial debt at EUR -115m from net cash at YE'22 (EUR 54m)
- Equity ratio of 45.3% (YE'22: 61.5%)



Capital allocation and usage of cash



2023

Key Highlights & Strategy (p.2)

Operational Performance (p.11)

Financial Performance (p.16)

Outlook (p.27)

Appendix (p.33)

Market Outlook 2024



- Current cyclical downturn impacts commodity business (SIA) harder due to weak construction- and yellow goods industries
- Diversified markets with different dynamics for SEA thus more resilient and stable with focus on technology and industrial solutions (e.g. mountain applications, mobility, healthcare)
- Challenging market conditions with first green shoots expected towards the end of 2024 at earliest





- Focus on industrial strategy with profitable growth, customer intimacy and technological leadership
- Distinctive industrial focus on two competitive business models
- Managing the downturn through share of wallet gains and cost programme
- Simplification, lean management and operational efficiency
- Setting up future growth platform for technical solutions and cost leadership



2024: EBITDA expected at

~EUR 80m

2024: CAPEX expected at

~EUR 70m

40% growth – 60% maintenance and small growth projects

Dividend proposal to the AGM

~EUR 0.50 per share

Five reasons to invest in Semperit

- Leading market position in elastomer applications with strong industrial base
- Relentless focus on innovation and technology
- Resilient business model driven by operating leverage and cost leadership
- Strong balance sheet and cash generation capacity
- Value play with recalibrated platform for future growth



Investor R	Relations	Sem	perit
-------------------	-----------	-----	-------

Financial Calendar 2024

Judit Helenyi, Director Investor Relations	19.03.2024	Publication of 2023 annual financial statements
	23.04.2024	Annual General Meeting, Vienna
+43 1 79777 - 310	15.05.2024	Report on 1-3 2024
www.semperitgroup.com/en/ir	13.08.2024	Half-year financial report 2024
Am Belvedere 10	07.11.2024	Report on 1-9 2024
1100 Vienna, Austria		

DISCLAIMER

The information provided in this presentation does not constitute an offer for the sale of securities nor an invitation to submit an offer to purchase shares of Semperit AG Holding, but exclusively serves information purposes.

The terms "Semperit" or "Semperit Group" in this presentation refer to the group; "Semperit AG Holding" or "Semperit Aktiengesellschaft Holding" is used to refer to the parent company (individual company).

We have prepared this presentation and verified the information it contains with the greatest possible care. Nevertheless, rounding, typesetting and printing errors cannot be ruled out. Rounding of differences in the summation rounded amounts and percentages may arise from the automatic processing of data.

The forecasts, plans and forward-looking statements contained in this presentation are based on the knowledge and information available and the assessments made at the time that this presentation was prepared. As is true of all forward-looking statements, these statements are subject to risk and uncertainties. As a result, actual events may deviate significantly from these expectations. No liability whatsoever is assumed for the accuracy of projections or for the achievement of planned targets or for any other forward-looking statements. Words such as "expect," "want", "believe," "anticipate," "includes," "plan," "assumes," "estimate," "projects," "intends," "should," "will," "shall," or variations of such words are generally part of forward-looking statements.

Furthermore, there is no guarantee that the contents are complete. Statements referring to people are valid for both men and women.





Key Highlights & Strategy (p.2)

Operational Performance (p.11)

Financial Performance (p.16)

Outlook (p.27)

Appendix (p.33)





Divisions & Group: 2023 vs 2022

in EUR m INDUSTRIAL APPLICATIONS (SIA) ENGINEERED APPLICATIONS (SEA) SEMPERIT GROUP

	2023	2022 ¹	%	2023 ²	2022 ¹	%	2023 ²	20221	%	
Revenue	330.8	450.2	-26.5%	351.0	283.8	23.7%	721.1	779.8	-7.5%	
EBITDA	46.9	88.0	-46.8%	50.5	37.2	35.8%	71.8	100.5	-28.5%	
EBITDA margin	14.2%	-19.6%	+5.4 PP	14.4%	13.1%	+1.3 PP	10.0%	12.9%	-2.9 PP	
EBITDA adjusted	46.9	88.1	-46.8%	56.9	32.5	75.2%	81.7	95.8	-14.7%	
EBITDA margin adjusted	14.2%	19.6%	-5.4 PP	16.2%	11.4%	+4.8 PP	11.3%	12.3%	-2.9 PP	
EBIT	29.7	67.9	-56.2%	33.2	28.1	18.4%	34.6	62.1	-44.3%	
EBIT margin	9.0%	15.1%	-6.1 PP	9.5%	9.9%	-0.4 PP	4.8%	8.0%	-3.2 PP	
EBIT adjusted	29.7	70.0	-57.5%	39.6	23.4	69.5%	44.5	65.4	-31.9%	
EBIT margin adjusted	9.0%	15.5%	-6.6 PP	11.3%	8.2%	+3.1 PP	6.2%	8.4%	-2.2 PP	
Earnings after taxes from continued operations	-	_	_	_	-	_	24.9	38.4	-35.2%	
Earnings after taxes from discontinued operations	_	_	_	_	_	_	-41.9	-44.0	-4.6%	
Earnings after tax	-	_	–	_	_	–	-17.1	-5.6	n.a.	
Earnings after tax adjusted							-8.1	3.8	n.a.	
Earnings per share in EUR	-	_	_	_	_	_	-0.82	-0.27	n.a.	
Additions in tangible and intangible assets	35.3	23.0	53.3%	240.0	9.2	n.a.	277.0	50.1	n.a.	

¹2022 adjusted for the one-off effect of the net proceeds from the property sale in France in the Belting division (2022: EBITDA, EBIT: EUR 4.7m; earnings after tax: EUR 4.0m), for the net impairments in the former Sempermed segment and the Profiles division (2022: EBIT EUR –7.9m; earnings after tax: EUR –12.3m) and for the transaction costs (2022: earnings after tax: EUR –8.2m).

² 2023 adjusted for one-off severance payments for changes to the Executive Board and for reductions in headcount (2023: EBITDA, EBIT: EUR –2.1m), one-off effects from the sale of the medical business (2023: EBITDA, EBIT: EUR –1.3m; earnings after tax: EUR –1.3m), transaction costs for Rico (2023: EBITDA, EBIT: EUR –3.3m, earnings after taxes: EUR –3.2m) and from profits of the Rico Group anticipated in the purchase price allocation (2023: EBITDA, EBIT: EUR –3.3m, earnings after taxes: EUR –2.3m).







Semperit Group (continued operations)

in EUR m SEMPERIT GROUP

	FY	Q1	Q2	Q3	Q4	FY	Q1	Q2	Q3	Q4	
	2021	2022	2022	2022	2022	2022	2023	2023	2023	2023	
Revenue	601.8	181.5	213.3	198.6	186.4	779.8	185.2	189.0	173.4	173.4	
EBITDA	54.0	20.3	33.7	25.9	20.7	100.5	20.8	22.9	13.1	15.0	
EBITDA margin	9.0%	11.2%	15.8%	13.0%	11.1%	12.9%	11.2%	12.1%	7.5%	8.7%	
EBIT	25.2	12.7	26.2	9.7	13.7	62.1	13.2	15.2	2.4	3.8	
EBIT margin	4.2%	7.0%	12.3%	4.9%	7.3%	8.0%	7.1%	8.1%	1.4%	2.2%	





2023

721.1

71.8

10.0%

34.6

4.8%



Semperit Industrial Applications, Semperit Engineered Applications & Corporate

in EUR m

SEMPERIT INDUSTRIAL APPLICATIONS (SIA)

Revenue EBITDA EBITDA margin EBIT EBIT margin

FY 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	FY 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	FY 2023
341.	9 111.1	126.4	111.6	101.1	450.2	99.4	93.0	72.2	66.2	330.8
59.	2 21.3	30.2	24.0	12.6	88.0	17.5	17.8	7.4	4.2	46.9
17.3	% 19.1%	23.9%	21.5%	12.5%	19.6%	17.6%	19.2%	10.2%	6.3%	14.2%
42.	1 16.6	25.7	17.4	8.1	67.9	12.9	13.5	3.1	0.2	29.7
12.3	% 14.9%	20.4%	15.6%	8.0%	15.1%	13.0%	14.5%	4.3%	0.3%	9.0%

SEMPERIT ENGINEERED APPLICATIONS (SEA)

Revenue
EBITDA
EBITDA margin
EBIT
EBIT margin

	FY	Q1	Q2	Q3	Q4	FY	Q1	Q2	Q3	Q4	FY
	2021	2022	2022	2022	2022	2022	2023	2023	2023	2023	2023
•	214.1	59.8	75.0	74.4	74.6	283.8	77.1	86.3	91.5	96.0	351.0
١	22.9	5.2	11.3	8.4	12.2	37.2	13.1	15.8	7.5	14.0	50.5
า	10.7%	8.7%	15.1%	11.3%	16.4%	13.1%	17.1%	18.3%	8.2%	14.6%	14.4%
Γ	14.7	3.0	9.1	6.1	9.8	28.1	10.7	13.2	1.9	7.5	33.2
ו [']	6.9%	5.1%	12.2%	8.2%	13.1%	9.9%	13.9%	15.3%	2.0%	7.8%	9.5%


CORPORATE


EBITDA EBIT

	FY	Q1	Q2	Q3	Q4	FY	Q1	Q2	Q3	Q4	FY	
	2021	2022	2022	2022	2022	2022	2023	2023	2023	2023	2023	
١.	-21.5	-3.2	-5.1	-2.2	-8.8	-19.4	-7.3	-8.6	-1.7	-3.3	-21.0	
Γ	-22.7	-3.5	-5.4	-2.5	-9.2	-20.6	-7.7	-9.0	-2.1	-3.6	-22.4	

Surgical Operations

Weak results driven by low demand and price levels





- Closing Sempermed sale (examination gloves and distribution) on August 31, 2023
- Contract manufacturing for Harps started on September 1, 2023
- Surgical results 1-8 2023 still burdened by fully running the surgical business with low demand, price pressure due to excess capacities and negative scale effects

in EUR m

KEY PERFORMANCE FIGURES

	2012	2013	2014 ¹	2015 ¹	2016 adj. ²	2017 adj. ³	2018 adj.⁴	2019 adj.⁵	2020 adj. ⁶	2021 ⁷	2022 adj. ⁷	2023 adj. ⁸
Revenue	828.6	906.3	858.3	914.7	852.4	874.2	875.5	840.6	927.5	601.8	779.8	721.1
EBITDA	108.7	132.5	101.9	96.2	74.7	35.8	50.3	63.8	208.6	54.0	95.8	81.7
EBITDA margin	13.1%	14.6%	11.9%	10.5%	8.8%	4.1%	5.7%	7.6%	22.5%	9.0%	12.3%	11.3%
EBIT	72.5	87.8	63.8	66.7	41.1	-0.8	15.4	28.2	171.4	25.2	65.4	44.5
EBIT margin	8.8%	9.7%	7.4%	7.3%	4.8%	-0.1%	1.7%	3.6%	18.5%	4.2%	8.4%	6.2%
Earnings after tax	46.1	54.9	37.8	46.4	15.2	-473.9	-17.3	-0.2	121.9	3.6	10.9	-8.1
EPS, in EUR	2.25	2.65	1.85	2.26	0.74	-2.08	-1.06	-0.33	5.53	10.8	-0.27	-0.82
Gross cash flow	85.6	116.2	89.9	55.7	48.1	32.2	37.4	46.7	193.7	323.4	30.5	24.4
Return on equity	11.4%	13.3%	8.6%	12.8%	4.6%	-15.8%	-4.2%	-16.3%	58.0%	45.7%	-1.1%	-4.0%

BALANCE SHEET KEY FIGURES

	2012	2013	2014 ²	2015 ²	2016	2017	2018	2019	2020	2021 ⁷	2022 ⁷	2023 ⁸
Balance sheet total	824.5	852.1	826.3	937.8	1,034.5	853.2	768.8	701.8	764.4	958.6	842.9	937.9
Equity	406.2	411.5	443.8	363.3	329.3	278.5	329.5	237.4	332.3	540.1	518.2	425.3
Equity ratio	49.3%	48.3%	53.7%	38.7%	31.8%	32.6%	42.9%	39.0%	43.5%	56.3%	61.5%	45.3%
Investments in tangible and intangible assets	41.2	49.7	67.4	71.8	65.1	74.5	80.8	31.9	26.4	34.6	37.6	277.0
Employees, at balance sheet date, FTEs	9,577	10,276	6,888	7,053	6,974	6,838	6,773	6,902	6,943	n.a.	4,269	4,576

¹ 2014 & 2015 restated. ² 2016 without profit contribution from SSC / Thai glove JV, impairment Sempermed and trade tax / levies in Brazil. ³ 2017 adjusted for positive one-off effects from JV transaction of EUR 85m (EUR 65m for net profit) and negative one-off effects from impairment at Sempermed (EUR 26m adj. EBIT, EAT only), from restructuring expenses in France (EUR 11m), valuation adjustment in IT (EUR 4m EBITDA, EUR 3m EBIT) & expenses resulting from tax audit in Austria (EUR 5m, mainly for refund of energy supply charge). ⁴ 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (EUR 4m for EBITDA, EUR 8m for EBIT and EAT) and for impairment of Sempermed of EUR 55m (adj. for EBIT and EAT only). ⁵ FY 2019 adjusted for positive one-off effects of EUR 4m (EBITDA, EBIT, EAT) due to release of provision in Sempermed for Brazilian court case for tax liabilities and for negative one-off effects of EUR 48.8m from impairment at Sempermed from impairment of Sempermed (adj. for EBIT and EAT). ⁶ 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2m EUR; earnings after tax effect: EUR +88.8m) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR -19.8m; earnings after taxes effect: EUR -16.1m) ¬ Numbers in 2021 and 2022 refer to new Group-structure, i.e reflect the sale of Sempermed; 2022: EBITDA, EBIT: EUR 4.7m; EAT: EUR 4.0m), for net impairments (2022: EBIT EUR -7.9m; EAT: EUR -12.3m) and for the transaction costs (2022: EBITDA, EBIT: EUR -8.2m). ⁶ 2023: EBITDA, EBIT: EUR -3.2m) and from profits of the Rico Group anticipated in the purchase price allocation (2023: EBITDA, EBIT: EUR -2.3m).



Overview price indices Butadiene

Price movements for raw materials¹⁾ became highly unpredictable

Price indices Butadiene as main raw material for synthetic rubber / latex




¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0





Overview price indices LFO-F-NWE / wire rod

Significant increase for raw material¹⁾ used in industrial segments



¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0





ESG targets adapted to the new Group structure

ESG Ratings: EcoVadis platinum award for second year in a row

CDP -Climate Change improved to C (after C-), first rating for Forest (C)

Diversity & Inclusion (D&I) as focus point introduced while also applying new targets

More ambitious goal set for supply chains to expand positive impact on Semperit's total sustainability footprint

Energy^{1,2}:

5% reduction by 2030

Waste²:

7% reduction by 2030

Emissions²:

10% reduction by 2030

Incidence rate^{1,2}:

8% reduction year over year

D&I Gender:

0.5% overall female increase 1% female leadership increase 1% higher senior leadership (annual change in each case)



Supply chain¹:

75% of total spend to be covered by EcoVadis by 2030





¹ Part of the ESG-based financing as of 31.8.2023

² Baseline 2023, including Rico and Surgical